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Letters to the Editor(2-dimensional and 3-dimensional
transthoracic and transesophageal
echocardiography, multidetector com-
puterized tomography scan) evalua-
tion of the annulus dimensions and
shape (the annulus is often oval and
not circular) and a semiquantitative
evaluation of the amount of calcium
on the annulus and the leaflets. In
fact, for the intermediate annulus di-
ameters, the choice of a larger or
a smaller valve depends on the
amount of calcium. A larger valve in
an extremely calcified annulus can
cause rupture of the aortoventricular
junction with consequent massive
hemorrhage. However, a small valve
in a poorly calcified annulus can lead
to paravalvular regurgitation or, more
dramatically, device embolization.
Correct positioning requires experi-
ence and a strong synergic coopera-
tion among all the components of the
transcatheter aortic valve implantation
team. The definition of valve malposi-
tioning includes not only a valve posi-
tioned too high or too low, but also
a problem of alignment between the
valve and longitudinal axis of the aor-
tic annulus. An asymmetric ‘‘diago-
nal’’ landing of the prosthesis on the
annulus might lead to paravalvular re-
gurgitation and to an abnormal
stress on the leaflets with a greater po-
tential risk of early structural
dysfunction.
In conclusion, we believe that even
if valve overexpansion might be care-
fully considered to reduce paravalvu-
lar leak, the transcatheter aortic
valve implantation results can be in-
creased mainly by improving patient
selection, annulus sizing, valve posi-
tioning, and cooperation among mem-
bers, as well as the experience of the
transcatheter aortic valve implanta-
tion team.
Augusto D’Onofrio, MD
Gino Gerosa, MD
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To the Editor:
We read with interest the 2-year
follow-up results of 227 patients with
amean age of 81 years who underwent
transcatheter aortic valve implantation
(TAVI) by Bleiziffer and colleagues.1
The authors have concluded that
there was ‘‘overall low morbidity at
2 years’’ and that the findings justify
offering TAVI to lower-risk octoge-
narians and high-risk younger pa-
tients. We do not concur with their
conclusions.
The 30-day mortality in the series
reported by Bleiziffer and colleagues1
was 12% with a periprocedural
cerebral vascular accident rate of
7%, a myocardial infarction rate of
4%, an acute kidney injury rate
of 10%, and an overall vascular com-
plication rate of 23% (8% of which
were major vascular events). Further-
more, 50% of patients had mild to
severe central and paravalvular regur-
gitation. The rate of pacemaker im-
plantation is not given; however, in
other TAVI series and in our hands it
is approximately 20%.
Before the introduction of TAVI in
the United Kingdom, the sixth na-
tional adult cardiac surgical databaseardiovascular Surgery c August 2012report, which was published in
2008,2 showed an overall mortality
of 2.8% for all isolated aortic valve
replacements and this figure was
5.5% to 5.8% in octogenarians.
We would like to share 2 other con-
cerns with the readers: The diagnosis
of porcelain aorta is made in nearly
10% of TAVI populations. This figure
is widely different from and higher
than what the surgical community
has experienced with aortic valve sur-
gery. Is it perhaps an over diagnosis?
Furthermore, the effect of balloon
dilatation on the integrity of the TAVI
prosthesis warrants attention. Insertion
of the Sapien valve (Edwards Life-
sciences, Irvine, Calif) requires bal-
loon expansion, and the practice of
further ballooning of Sapien or Core-
Valve prostheses (Medtronic, Inc,Min-
neapolis, Minn) to reduce paravalvular
leak may affect the integrity and thus
durability of these valves.
We appreciate that the TAVI cohort
probably has a higher EuroSCORE or
Society of Thoracic Surgeons score.
We are a main TAVI center in the
United Kingdom, with significant sur-
gical input and driving force, but we
believe that unless the results and out-
comes can match surgery to some ex-
tent, TAVI should not be expanded to
younger or lower-risk patients.
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